3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
sargramostim
2
Topotecan
2
timcodar
1
bempegaldesleukin
1
Tissue Plasminogen Activator
1
Radiotherapy
1
Radiosurgery
1
Paclitaxel
1
Muromonab-CD3
1
Irinotecan
1
Interferon-alpha
1
Immunization, Passive
1
Gemcitabine
1
Docetaxel
1
Diathermy
1
Cyclophosphamide
1
Cisplatin
1
Captopril
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Unspecified Adult Solid Tumor, Protocol Specific
×
bempegaldesleukin
×
Clear all
NCT02869295
2021-07-29
NKTR-214
Nektar Therapeutics
Phase 1/2
Completed
28 enrolled
16 charts